Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Silence Therapeutics

    NASDAQ: SLN · Real-Time Price · USD
    5.77
    -0.18 (-3.03%)
    At close: Jun 23, 2025, 3:59 PM
    5.77
    0.00%
    Pre-market: Jun 24, 2025, 08:00 AM EDT
    -3.03%
    Bid 4.29
    Market Cap 272.52M
    Revenue (ttm) 26.21M
    Net Income (ttm) -56.93M
    EPS (ttm) -1.53
    PE Ratio (ttm) -3.77
    Forward PE -14.52
    Analyst Buy
    Ask 7.33
    Volume 116,586
    Avg. Volume (20D) 215,653
    Open 5.95
    Previous Close 5.95
    Day's Range 5.66 - 6.14
    52-Week Range 1.97 - 22.46
    Beta 1.41

    About SLN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SLN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SLN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 months ago
    -15.45%
    Silence Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
    news image

    1 week ago · businesswire.com

    Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

    LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) th...

    news image

    2 weeks ago · zacks.com

    Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

    The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

    news image

    1 month ago · zacks.com

    Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

    The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...

    news image

    1 month ago · businesswire.com

    Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

    LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...

    news image

    1 month ago · businesswire.com

    Silence Therapeutics Welcomes Tim McInerney to Board of Directors

    LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...

    Add to Watchlist